source
- Zenidatamab regimens show survival benefit in HER2-positive gastric cancer, but PD-L1 test variability raises treatment questionsThe HERIZON‑GEA‑01 study reports that zenidatamab‑based treatment schedules lead to a notable improvement in overall survival for patients with HER2‑positive gastric cancer. These efficacy finding…
- Dr. Jones reports GLP-1 agonists may outperform aspirin in colorectal cancer prevention and tolerabilityDr. Colton Jones presented findings from a retrospective analysis that compared GLP-1 receptor agonists with aspirin for primary prevention of colorectal cancer. The analysis indicated that patien…onclive · 3mo agoPositive readoutPositive